Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Activation of guanylate cyclase C signaling pathway protects intestinal epithelial cells from acute radiation-induced apoptosis.

Garin-Laflam MP, Steinbrecher KA, Rudolph JA, Mao J, Cohen MB.

Am J Physiol Gastrointest Liver Physiol. 2009 Apr;296(4):G740-9. doi: 10.1152/ajpgi.90268.2008. Epub 2009 Feb 12.

2.

Cellular effects of guanylin and uroguanylin.

Sindić A, Schlatter E.

J Am Soc Nephrol. 2006 Mar;17(3):607-16. Epub 2005 Dec 28. Review.

3.

Pendrin, a novel transcriptional target of the uroguanylin system.

Rozenfeld J, Tal O, Kladnitsky O, Adler L, Efrati E, Carrithers SL, Alper SL, Zelikovic I.

Cell Physiol Biochem. 2013;32(7):221-37. doi: 10.1159/000356641. Epub 2013 Dec 18. Review.

4.

Can colorectal cancer be prevented or treated by oral hormone replacement therapy?

Li P, Lin JE, Schulz S, Pitari GM, Waldman SA.

Curr Mol Pharmacol. 2009 Nov;2(3):285-92. Review.

5.
6.

Transmembrane guanylate cyclase in intestinal pathophysiology.

Steinbrecher KA, Cohen MB.

Curr Opin Gastroenterol. 2011 Mar;27(2):139-45. doi: 10.1097/MOG.0b013e328341ead5. Review.

PMID:
21102322
7.

The multiple and enigmatic roles of guanylyl cyclase C in intestinal homeostasis.

Arshad N, Visweswariah SS.

FEBS Lett. 2012 Aug 31;586(18):2835-40. doi: 10.1016/j.febslet.2012.07.028. Epub 2012 Jul 20. Review.

8.
9.

GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome?

Li P, Lin JE, Marszlowicz GP, Valentino MA, Chang C, Schulz S, Pitari GM, Waldman SA.

Drug News Perspect. 2009 Jul-Aug;22(6):313-8. doi: 10.1358/dnp.2009.22.6.1395254. Review.

10.

Mechanisms of actions of guanylin peptides in the kidney.

Sindić A, Schlatter E.

Pflugers Arch. 2005 Aug;450(5):283-91. Epub 2005 Jun 11. Review.

PMID:
15952032
11.

Molecular physiology of natriuretic peptide signalling.

Kuhn M.

Basic Res Cardiol. 2004 Mar;99(2):76-82. Epub 2004 Jan 23. Review.

PMID:
14963665
12.

E. coli heat-stable enterotoxin and guanylyl cyclase C: new functions and unsuspected actions.

Giannella RA, Mann EA.

Trans Am Clin Climatol Assoc. 2003;114:67-85; discussion 85-6. Review.

13.

Molecular Physiology of Membrane Guanylyl Cyclase Receptors.

Kuhn M.

Physiol Rev. 2016 Apr;96(2):751-804. doi: 10.1152/physrev.00022.2015. Review.

14.

Mechanisms of guanylin action via cyclic GMP in the kidney.

Forte LR, London RM, Krause WJ, Freeman RH.

Annu Rev Physiol. 2000;62:673-95. Review.

PMID:
10845107
15.

Genetic mouse models of the NO receptor 'soluble' guanylyl cyclases.

Mergia E, Koesling D, Friebe A.

Handb Exp Pharmacol. 2009;(191):33-46. doi: 10.1007/978-3-540-68964-5_3. Review.

PMID:
19089324
16.

Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain.

Hannig G, Tchernychev B, Kurtz CB, Bryant AP, Currie MG, Silos-Santiago I.

Front Mol Neurosci. 2014 Apr 16;7:31. doi: 10.3389/fnmol.2014.00031. eCollection 2014. Review.

17.

A new Rac/PAK/GC/cGMP signaling pathway.

Guo D, Zhang JJ, Huang XY.

Mol Cell Biochem. 2010 Jan;334(1-2):99-103. doi: 10.1007/s11010-009-0327-7. Epub 2009 Nov 24. Review.

18.

Current understanding of guanylin peptides actions.

Sindic A.

ISRN Nephrol. 2013 Apr 17;2013:813648. doi: 10.5402/2013/813648. eCollection 2013. Review.

19.

The multiple roles of guanylate cyclase C, a heat stable enterotoxin receptor.

Steinbrecher KA.

Curr Opin Gastroenterol. 2014 Jan;30(1):1-6. doi: 10.1097/MOG.0000000000000020. Review.

PMID:
24304979
20.

Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target.

Lin JE, Li P, Pitari GM, Schulz S, Waldman SA.

Future Oncol. 2009 May;5(4):509-22. doi: 10.2217/fon.09.14. Review.

Supplemental Content

Support Center